<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916695</url>
  </required_header>
  <id_info>
    <org_study_id>XV02RS</org_study_id>
    <secondary_id>XV02RS</secondary_id>
    <nct_id>NCT00916695</nct_id>
  </id_info>
  <brief_title>Everolimus-Eluting Stent for Bifurcation Coronary Lesions: Comparison of Simple Versus Complex Techniques</brief_title>
  <official_title>Everolimus-Eluting Stent in the Treatment of Bifurcation Lesions: Comparison of Main Vessel Stent to Main Vessel and Side Branch Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Society of Cardiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of the treatment of true
      bifurcation lesions with the XIENCE V stent using the simple strategy (stent in main vessel
      and provisional T-stenting in the side branch) compared to the complex strategy (stent in
      main vessel and T-stenting in the side branch).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">February 2011</completion_date>
  <primary_completion_date type="Anticipated">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the rate of binary angiographic restenosis (in main vessel and side branch) in the simple versus complex strategy groups</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined rate of events (cardiac death, myocardial infarction and TLR)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">332</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Complex PCI strategy for bifurcation coronary lesions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stenting main vessel and T-stenting for the side branch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simple PCI strategies for bifurcation coronary lesions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stenting main vessel, with provisional stenting for the side branch.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.</intervention_name>
    <description>Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.
Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique.</description>
    <arm_group_label>Complex PCI strategy for bifurcation coronary lesions</arm_group_label>
    <arm_group_label>Simple PCI strategies for bifurcation coronary lesions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years old.

          -  True Bifurcation lesion (Medina classification 1-1-1), in at least one main coronary
             vessel. Diameter of main vessel between 2,5-4mm, and diameter of side branch 2mm or
             greater.

        Exclusion Criteria:

          -  Significant left main stenosis.

          -  ST elevation myocardial infarction &lt; 48 h.

          -  Thrombus burden target lesion.

          -  Ejection Fraction &lt; 30%.

          -  Severe Renal Insufficiency (creatinine &gt; 3 mg/dl).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Gimeno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico Universitario Valladolid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Valle de Hebron. Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramiro Trillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Santiago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Moreu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de la Salud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Goicolea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Puerta de Hierro. Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raul Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose F Diaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Juan Ramon Jimenez. Huelva</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose M Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico de Malaga</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramon Lopez-Palop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Juan. Alicante</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariano Valdes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascual Bordes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario. Alicante</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose R Rumoroso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Galdakao. Vizcaya</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rafael J Ruiz-Salmeron, PhD</last_name>
    <phone>0034955693440</phone>
    <email>rjruizsalmeron@yahoo.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael J Ruiz-Salmeron, PhD</last_name>
      <phone>+34955693440</phone>
      <email>rjruizsalmeron@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <zip>41007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael j Ruiz-Salmeron, PhD</last_name>
      <phone>0034955693449</phone>
      <email>rjruizsalmeron@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Rafael J Ruiz-Salmeron, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Vizcaino, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergio Rodriguez-Leiras, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cesar Carrascosa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Marcos, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2009</study_first_posted>
  <last_update_submitted>July 22, 2009</last_update_submitted>
  <last_update_submitted_qc>July 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Fernando Martín Burrieza</name_title>
    <organization>Spanish Society of Cardiology</organization>
  </responsible_party>
  <keyword>Stents</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Bifurcation Coronary Lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

